EP1430052A2

EP1430052A2 - Substituted imidazo 1, 2-a]-5, 6, 7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo 1, 2-a]pyridines

Info

Publication number: EP1430052A2
Application number: EP02776963A
Authority: EP
Inventors: Hagen Weigl; Klaus Ebel
Original assignee: BASF SE
Current assignee: BASF SE
Priority date: 2001-09-14
Filing date: 2002-09-03
Publication date: 2004-06-23
Also published as: DE10145457A1; HUP0401991A3; WO2003024963A3; CA2459960A1; JP2005504079A; WO2003024963A2; HUP0401991A2; US7196196B2; US20050020620A1

Abstract

The invention relates to a method for producing imidazo[1, 2-a]-5, 6, 7,8-tetrahydropyridine-8-ones, by reacting η-butyrolactones with imidazoles. The invention also relates to novel imidazo[1, 2-a]-5, 6, 7,8-tetrahydropyridine-8-ones and the use thereof for producing imidazo[1, 2-a]pyridines.

Description

Substituted imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one, process for their preparation and their use in the preparation of imidazo [1,2-a] pyridines

description

The invention relates to substituted imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-ones, processes for their preparation and their use for the preparation of imidazo [1,2-a] pyridines.

Imidazo [1,2-a] pyridines represent an economically extremely interesting class of compounds in the field of pharmaceuticals, crop protection agents and cosmetics.

Imidazo [1,2-a] pyridines are mainly used for the prevention and treatment of various diseases, such as gastrointestinal diseases, cancer or diseases of the central nervous system. The preparation and use of such compounds is described. For example for the treatment of gastrointestinal diseases such as gastric ulcers (Kaminski JJ et al. (1987) J Med Chem 30: 2031-2046; DE 28 20 938, WO 98/54188, WO 98/37080, DE 19602853, EP 0 308 917, EP 0 268 989, US 6,124,313, US 6,096,758, US 6,132,768, WO 96/03 * 405, WO 96/03402, US 5574042, WO 95/10518, EP 596 406, WO 94/18199, WO 89/00570, EP 0 290 003, EP 0 228 006, EP 0 204 285, EP 068 378, EP 033 094). As a product example, Solimidine® (Zolimidine ^® also Zoliridine ^®; 2 [4-methyl sulfonyDphenyl] imidazo [1,2-a] pyridine) to call. As kardiotoni- ULTRASONIC drug is also of the cAMP phosphodiesterase inhibitor oprinone® to call (Olprinone ^®, 1,2-dihydro-5-imidazo [1, 2-a] - pyridin-6-yl-6-methyl-2-oxo-3 -pyridine carbonitrile). Imidazo [1, 2-a] pyridines are also used in non-benzodiazepine hypnotics such as zolpidem (N, N, 6-trimethyl-2-p-tolyl-imidazo [1,2a] -pyridine-3-acetamide). As curare mimetic is further Fazadinium- bromide to give (Fazadon ^®; 1, l'-azobis [3-methyl-2-phenyl-imidazo [1,2-a] pyridiniumdibromid). Alpidem® is also known as an anxiolytic (Ananxyl®, 6-chloro-2- (4-chlorophenyl) - N, N-dipropyl-imidazo [1,2-a] yridine-3-acetamide). For the treatment of osteoporosis, Minodronic Acid (YM-529) is evaluated in clinical studies (1-hydroxy-2-imidazo [1, 2-a] pyridin-3-ylethylidene bisphosphonic acid). Other imidazo [1, 2a] pyridines are in clinical trials as promising bradikinin (BK) B2 receptor antagonists (8- [[3- (N-acylglycl-N-methylamino) -2, 6-dichlorobenzyl] oxy] 3- halo-2-methylimidazo- [1, 2-a] pyridines; Abe Y et al. (1998) J Med Chem 41: 564-578). Finally, imidazo [1,2a] pyridines also go into nucleoside analogues which are used as antiviral therapeutics or in cancer therapy (chemotherapy) (Pan SF et al. (1998) Tetrahedron Letters 39: 8191-8194). Other compounds of this type of structure are described as interleukin-6 inhibitors (for example 2,3,7,8-tetrahydro-4-aryl-1H-cyclopent [e] imidazo [1,2-a] - pyridine-5 (6H) - on; Tagat J et al. (1995) Bioorg. Med. Chem. Lett. 5 (18): 2143-2146).

Imidazo [1,2-a] pyridines are used in cosmetics, for example, as coupling components in oxidative hair colorants (EP 0 930 062).

Imidazo [1,2-a] pyridines are also interesting building blocks in crop protection products. Herbicides such as sulfosulfuron ^® (Maverick ^®, 1- (2-ethylsulphonyl-imidazo [l, 2-a] pyridin-3-yl-sulfonyl) -3- (4,6-demethoxypyrimidin-2-yl) -harnstof) or imazosulfuron ^® (Takeoff ^® , 1- (2-chloro-imidazo [1,2-a] pyridin-3-yl-sulfonyl) -3- (4,6-dimethoxypyrimidin-2-yl) urea) include this grouping.

These compounds are generally synthesized. from the corresponding pyridine derivatives to which the idazole ring is fused using different reaction pathways (Kaminski JJ et al. (1987) J Med Chem 30: 2031-2046; see also the above-mentioned property rights). The reaction usually involves several reaction steps and requires the availability of mostly expensive starting materials.

WO 98/42707 outlines the preparation of pharmaceuticals based on imidazo- [1,2a] -tetrahydropyridin-8-ones in the context of a hypothetical synthesis process (p. 16 / scheme 8). However, the application does not contain any technical teaching on how these connections are technically accessible.

Only imidazo- [1,2a] -tetrahydropyridin-8-one is described in the literature as the natural product sibyllimycin (3-methyl-imidazo- [1, 2a] - tetrahydro-pyridin-8-one) and a process for its preparation (Hafenbradl et al. (1996) Angew. Chem. Int. Ed. Engl. 33 (5): 545-547). This synthesis is complex, has several stages and is based on the N-alkylation of 4-methylimidazole with 4-bromobutyronitrile, cyclization using butyllithium and subsequent hydrolysis of the imine formed. The thermal reaction of γ-butyrolactones with 4,5-unsubstituted imidazoles has been described and leads to N-alkylated or N-acylated imidazoles without ring closure being observed. Elevated temperatures (220 ° C) lead to the addition of several butyrolactone molecules and - with longer reaction times - to tar formation (Shecchenko OK et al. (1992) Khi Geterotskikl Soedin 11, 1491-1493).

The task was to provide new starting materials and processes for the preparation of imidazo [1,2a] pyridines.

Surprisingly, this was achieved by providing imidazo [1,2a] -5, 6,7, 8-tetrahydropyridin-8-ones and new processes for the preparation of the same.

A first object of the invention relates to processes for the preparation of imidazo- [1, 2a] -5, 6, 7, 8-tetrahydropyridin-8-ones, characterized in that

a) reacting a γ-butyrolactone with an imidazole which has at least one substitution in position 4 or 5, and

b) the imidazo- [1,2a] -5, 6,7, 8-tetrahydropyridin-8-one isolated.

The reaction can take place thermally at temperatures above 100 ° C., preferably at temperatures from 100 to 300 ° C., particularly preferably at temperatures from 150 to 250 ° C., very particularly preferably at temperatures from 190 to 220 ° C.

The reaction can be carried out without any additional activation or else by activation by adding bases, acids or catalysts. The activation is preferably base-catalyzed. Preferred bases are potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, DBU (1,5-diaza-bicyclo [5.4.0] undecylene-5), trialkylamines, LDA (lithium diisopropyl amide) and Hunig base (diisopropylethylamine).

The reaction of the imidazoles can be carried out with equimolar amounts of butyrolactone or an excess of one of the two starting materials - imidazole or γ-butyrolactone. The excess can be at least 20 mol%, preferably at least 50 mol%, particularly preferably at least 100 mol%, very particularly preferably at least 500 mol%. The preferred range of excess is between 300 mol% and 500 mol%. The reaction is preferably carried out with an excess of γ-butyrolactone, which simultaneously serves as a solvent and for trapping the water of reaction. In an advantageous embodiment, the excess γ-butyrolactone can possibly be partially or completely distilled off together with the water of reaction formed during or after the reaction. The isolated yield can be increased if part of the butyrolactone is distilled off during or after the reaction.

In a further embodiment, other solvents, such as, for example, toluene or xylene, can be added to the reaction mixture, which, for example in the function of a tractor, promote the removal of the water of reaction.

The reaction can be carried out at normal pressure, elevated or reduced pressure. The pressure can be kept constant during the reaction or else can be modulated, for example for the purpose of distilling off a solvent. The reaction is preferably carried out at normal pressure.

The response time depends on the speed of implementation. For example, it can be approximately 12 hours.

The imidazo- [1,2a] -5, 6,7, 8-tetrahydropyridin-8-one can then be precipitated, for example, by cooling the batch and separated by solid / liquid separation (“suction”).

Methods known to those skilled in the art such as column chromatography, high pressure liquid chromatography or recrystallization, falling over, zone melting, distillation, washing with suitable solvents such as acetone, dibutyl ether, dibutyl ketone, isobutyl methyl ketone are used as methods for purifying the crude product.

In a preferred embodiment, the invention 6 7 relates to methods for the preparation of imidazo [1,2-a] -5, 8-tetrahydro- pyridin-8-ones of the formula Ia or Ib, ^{"characterized} in that

a) γ-butyrolactones of the formula III with imidazoles of the formula Ha or Ilb, where the imidazole has at least one substitution in position 4 or 5, and

b) Imidazo [1,2a] -5, 6, 7, 8-tetrahydro-pyridinones of the formula Ia or Ib can be isolated.

Ia ib

It is known to the person skilled in the art that imidazoles of the general formula Ha and Ilb can be converted into one another as a result of a tautomerism.

Suitable substituents on the imidazole and / or butyrolactone which are used in the process according to the invention are preferably those which meet the conditions of the invention

Withstand the process without leading to an increased proportion of by-product or decomposition product. Educts are preferably used which decompose under the reaction conditions by a maximum of 50%, preferably a maximum of 20%, particularly preferably a maximum of 10%.

In a particular embodiment, the starting materials or individual substituents thereof used in the process according to the invention can be derivatized for the period of the reaction in the manner familiar to those skilled in the art or modified by known protective groups in order to improve the stability of the compounds under the conditions of the process according to the invention to increase. Preferred derivatization or modification methods are oxidation, reduction, 0-, S- or N-alkylation or acylation, such as esterification, etherification or acetal formation. For example, hydroxyl groups can be protected by introducing protective groups such as trityl, tert-butyldimethylsilyl, tert-butyloxycarbonyl (BOC), THP ether or benzyl groups. Carbonyl groups can be protected by acetal formation. Thiols as thioesters or thioethers; Amines as carbamates, ^" amides or benzylamines. The invention further relates to substituted imidazo- [1,2a] - 5,6, 7, 8-tetrahydropyridin-8-one described by the general formula Ia or Ib or salts thereof with the proviso that

a) Rl, R2 and all radicals R3 do not simultaneously represent hydrogen, or

b) if Rl and all radicals R3 represent hydrogen, then R2 is not methyl, or

c) if R2 and all radicals R3 represent hydrogen, then R1 is not methyl,

where the number of substituents R3 can assume a value n between 1 and 6.

The following applies to the processes according to the invention and the substituted imidazo- [1,2a] -5, 6,7, 8-tetrahydropyridin-8-ones according to the invention, preferably in the general formulas Ia, Ib, Ha, Ilb or III mentioned above:

R1, R2 or each R3 can in each case and independently of one another be selected from the group consisting of hydrogen, halogen, hydroxy, cyano, isocyano, thiocyano, amino, nitroso, nitro, carbonyl, alkylcarbonyl, sulfonate, alkylsulfonyl, sulfonamide, Sulfonylurea, carboxyl, alkylcarboxyl, substituted or unsubstituted, branched or unbranched or cyclic alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl or heteroaryl.

R 1, R 2 or each R 3 are in each case selected independently and independently of one another from the group consisting of hydrogen, hydroxyl, halogen, cyano, thiocyanato, branched or unbranched, optionally substituted Cχ-C ₆ -alkyl, ^' C ₂ -C ₆ -Alkenyl, C -C ₆ -alkynyl, C ₃ -C -cycloalkyl, C ₃ -C ₆ -alkadienyl, hydroxy-Ci-Cg-alkyl, halo -CC-C ₆ alkyl, Ci-Cε-alkoxy, C ₂ -C ₆ -alkenyl-oxy, C -C ₆ -alkynyloxy, Ci-Cg-alkyl-oxy-Ci-Cg-alkyl, Ci-Cδ-alkyl-oxy-C ₂ -C ₆ -alkenyl, Cι-C ₆ - Alkyl-oxy-C ₂ -C ₆ -alkynyl, cyano-Ci-Cg-alkyl, isocyano-Ci-C _ß -alkyl, amino-Cι-C ₆ -alkyl, amino-C ₂ -Cg-alkynyl, CO-Cι -C ₆ alkyl, Ci-Cß-alkylsulfonyl, mono- or disubstituted - N- (Ci-C _ß- alkyl) sulfonamide, sulfonylurea, sulfonate, carboxyl, -C-C ₆ alkylcarboxyl, carbonyl, formyl, alkylcarbonyl, aryl , Arylalkyl, heteroaryl and heteroarylalkyl, preferred substituents being halogen, hydroxy, cyano, isocyano, thiocyano, amino, nitroso, nitro, alkoxy, alkenyloxy, alkynylox y, carbonyl or alkylcarbonyl, carboxyl or alkylcarboxyl. R1 and R2 can preferably also form a ring system together, so that a bicyclic imidazole is used and a tricyclic imidazo- [1, 2a] -5, 6, 7, 8-tetrahydropyridin-8-one is obtained.

If one of the starting materials used contains a chirality center, one of the two enantiomers is preferably used in the reaction.

The following applies in particular to the selection of Rl, R2 or each R3, independently of one another:

a) the halogen is fluorine.

b) -C ₆ alkyl is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, 1-methyl-propyl, 2nd -Methyl-propyl, n-pentyl, iso-pentyl, n-hexyl and iso-hexyl. Most preferred are methyl, ethyl, n-propyl and iso-propyl.

c) C ₂ -C ₆ alkenyl is selected from the group consisting of ethenyl, 1-propenyl, 2-propenyl, n-1- (or 2 or 3) -butenyl, iso-butenyl, nl- (or 2 or 3 or 4) pentenyl, iso-pentenyl, n-1- (or 2 or 3 or 3 or 5) -hexenyl and iso-hexenyl. Most preferred are ethenyl, 1-propenyl and 2-propenyl. _, id) C ₃ -C ₆ alkadienyl is selected from the group consisting of 1,2-propadienyl, n-butadien-1, 3-yl, n-butadien-l, 2-yl, n-butadiene-2,3 -yl, iso-butadienyl, n-pentadienyl, iso-pentadienyl, n-hexadienyl and iso-hexadienyl. Most preferred are 1,2-propadienyl and n-butadien-1,3-yl.

e) C -C ₆ -alkynyl is selected from the group consisting of ethynyl, 1-propynyl, 2-propynyl, n-butyn-1-yl, n-butyn-2-yl, n-butyn-3-yl, l -Methyl-propin-2-yl, n-pentyn-1-yl, isopentinyl, n-hexynyl, iso-hexynyl Most preferred are ethynyl, 1-propynyl and 2-propynyl.

f) C ₃ -C -cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclohexyl. R1 and R2 can preferably also form a ring system together, so that a bicyclic imidazole is used and a tricyclic imidazo- [1, 2a] -5, 6, 7, 8-tetrahydropyridin-8-one is obtained. R1 and R2 preferably form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclohexyl ring system. g) Halo-Cχ-Cg-alkyl is selected from the group consisting of halomethyl, haloethyl, n-halopropyl, iso-halopropyl, n-halobutyl, tert-halobutyl, halo-1-methyl-propyl, halo-2-methyl- propyl, n-halopentyl, iso-halopentyl, n-halohexyl and iso-halohexyl. Halomethyl, haloethyl, n-halopropyl and iso-halopropyl are most preferred. One or more halogen substitutions are allowed. The halogen is preferably fluorine. Most preferred is trifluoromethyl.

h) Hydroxy-Ci-C _ß- alkyl is selected from the group consisting of hydroxymethyl, hydroxyethyl, n-hydroxypropyl, iso-hydroxypropyl, n-hydroxybutyl, tert-hydroxybutyl, hydroxy-1-methyl-propyl, hydroxy-2-methyl -propyl, n-hydroxypentyl, iso-hydroxypentyl, n-hydroxyhexyl and iso-hydroxyhexyl. Most preferred are hydroxymethyl, hydroxyethyl, n-hydroxypropyl and iso-hydroxypropyl.

i) Ci-Cg-alkoxy is selected from the group consisting of

Methoxy, ethoxy, n-propoxy, 1-propoxy, n-butoxy, sec-butoxy, tert-butoxy, amyloxy, isoamyloxy and tert-amyloxy. Most preferred are methoxy, ethoxy, n-propoxy and i-propoxy.

j) CC ₆ _alkenyloxy is selected from the group consisting of ethenoxy, n-propenyloxy, isopropenyloxy, n-butenyloxy and sekiButenyloxy.

k) C ₂ -Cg_alkynyloxy is selected from the group consisting of ethynyloxy, n-propynyloxy, isopropynyloxy, n-butynyloxy and sec-butynyloxy.

1) Cι-Cg_Alkyl-oxy-Cι-C ₆ alkyl is selected from the group consisting of methoxymethyl, ethoxymethyl, propoxymethyl, methyloxyethyl, ethoxyethyl, propoxyethyl, methoxypropyl, ethoxypropyl and propoxypropyl.

m) -C-C ₅ _Alkyl-oxy-C-Cg-alkenyl is selected from the group consisting of methyloxyethenyl, ethoxyethenyl, propoxy-ethenyl, methoxypropenyl, ethoxypropenyl and propoxypropenyl.

n) -C ₆ -Alkyloxy-CC ₆ -alkynyl is selected from the group consisting of methyloxyethynyl, ethoxyethynyl, propoxyethynyl, methoxypropynyl, ethoxypropynyl and propoxypropynyl. o) C -C ₆ alkenyloxy-Cι-Cg-alkyl is selected from the group consisting of ethenoxymethyl, propenoxymethyl, ethenoxyethyl, propenoxyethyl, ethenoxypropyl and propenoxypropyl.

p) Cι-Cg_Alkyl-oxy-C ₂ -C ₆ alkynyl is selected from the

Group consisting of ethinoxymethyl, propinoxymethyl, ethinoxyethyl, propinoxyethyl, ethinoxypropyl and propinoxypropyl.

q) Cyano-Ci-Cg-alkyl is selected from the group consisting of cyanomethyl (acetonitrile), cyanoethyl, n-cyanopropyl, iso- cyanopropyl, n-cyanobutyl, tert-cyanobutyl, cyano-1-methyl-propyl, cyano-2 -methyl-propyl, n-cyanopentyl, iso-cyano-pentyl, n-cyanohexyl and iso-cyanohexyl. Most preferred are cyanomethyl (acetonitrile), cyanoethyl, n-cyanopropyl and iso-cyanopropyl.

r) Isocyano-Ci-Cg-alkyl is selected from the group consisting of isocyanomethyl, isocyanoethyl, n-isocyanopropyl, iso-isocyanopropyl, n-isocyanobutyl, tert-isocyanobutyl, iso-cyano-1-methyl-propyl, isocyano-2- methyl-propyl, n-isocyano-pentyl, iso-isocyanopentyl, n-isocyanohexyl, iso-isocyano-hexyl. Most preferred are isocyanomethyl, isocyanoethyl, n-isocyanopropyl and iso-isocyanopropyl.

s) amino-Ci-Cg-alkyl is selected from the group consisting of aminomethyl, aminoethyl, n-aminopropyl, iso-aminopropyl, n-aminobutyl, tert-aminobutyl, amino-1-methyl-propyl, amino-2-methyl propyl, n-aminopentyl, iso-aminopentyl, n-aminohexyl, iso-aminohexyl. Most preferred are aminomethyl, aminoethyl, n-aminopropyl and iso-aminopropyl.

t) Amino-CC ₆ -alkynyl is selected from the group consisting of aminoethynyl, 1-amino-1-propynyl, l-amino-2-propynyl, n-1-amino-butyn-l-yl, nl-amino-butyne -2-yl, n-1-amino-butyn-3-yl, l-amino-3-methyl-propyn-1-yl, n-1-amino-pentynyl, n-1-amino-hexynyl. Most preferred are aminoethynyl, 1-amino-l-propynyl and l-amino-2-propynyl.

u) Cχ-Cg_Alkylcarboxyl is selected from the group consisting of methylcarboxyl, ethylcarboxyl and propylcarboxyl. ^"

v) C ₃ -C ₆ cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, imidazole and piperidine. w) Ci-Cg-alkylsulfonyl is selected from the group consisting of methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, (1-methyl-propyl) sulfon , 2-methyl-propylsulfonyl, n-pentylsulfonyl, isopentylsulfonyl, n-hexylsulfonyl and iso-hexylsulfonyl. Most preferred are methylsulfonyl, ethylsulfonyl, n-propylsulfonyl and iso-propylsulfonyl.

x) With regard to the mono- or disubstituted N- (Ci-Cg-alkyl) - sulfonamide, the alkyl is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec -Butyl, tert-butyl, 1-methyl-propyl, 2-methyl-propyl, n-pentyl, isopentyl, n-hexyl and iso-hexyl, particularly preferably from the group consisting of methyl, ethyl, n- Propyl and isopropyl. Both substituents are very particularly preferably identical with regard to the disubstituted N, N- (Cχ-C-alkyl) sulfonamides.

y) sulfonylurea can be substituted or unsubstituted, preferably substituted. The substitution can include substituted or unsubstituted alkyls or aryls or heteroaryls. L-Sulfonyl-3 (4, 6-dimethoxypyrimidin-2-yl) urea is very particularly preferred.

z) Aryl is selected from the group consisting of substituted and unsubstituted benzyl, substituted and unsubstituted naphthyl, very particularly preferred are phenyl, tolyl, xylyl, 1-naphthyl, 2-naphthyl, 1-anthryl and 2-anthryl ,

aa) Heteroaryl is selected from the group consisting of substituted and unsubstituted aromatic heterocycle, substituted and unsubstituted aromatic or partially aromatic heterobicyclic, the heterocycles being 5 or 6-membered rings and up to 3 heteroatoms selected from the group N, 0, S can contain.

In a preferred embodiment, the process according to the invention is carried out starting from imidazoles which each have a substitution different from hydrogen in position ^* 4 and position 5.

In a particularly preferred embodiment, the process according to the invention is carried out starting from imidazoles, each of which has an identical substitution different from hydrogen in position 4 and position 5. This embodiment is particularly advantageous since only one product is formed and the compounds of the general formulas Ia and Ib correspond. Since the yields on the desired product are particularly good here, this embodiment can be realized in an economically particularly advantageous manner.

The substituted imidazo- [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-ones according to the invention preferably comprise those which each have a substitution different from hydrogen in position 2 and position 3. These substitutions in positions 2 and 3 which are different from hydrogen are very particularly preferably identical.

Very particularly preferred combinations of R1, R2 and R3 with respect to the imidazo [1, 2-a] -5, 6, 7, 8-tetrahydropyridin-8-one to be prepared by the process according to the invention are mentioned below:

1. R3 = H, Rl = R2 = methyl. Γ-Butyrolactone and 4,5-dimethylimidazole or derivatives or modifications of the aforementioned are used. 2, 3-Dimethyl-imidazo [1, 2-a] - 5,6,7, 8-tetrahydropyridin-8-one is formed.

2. R3 = H, Rl = H, R2 = methyl. Γ-Butyrolactone and f4-methylimidazole (or alternatively 5-methylimidazole) are used.

2-Methylimidazo [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-one and 3-methylimidazo [1, 2a] -5, 6, 7, 8-tetrahydropyridin-8- on.

3. R3 = H, R2 = methyl, Rl = acetonitrile (cyanomethyl). Γ-Butyrolactone and 4-acetonitrile-5-methylimidazole or 5-acetonitrile-4-methylimidazole or derivatives or modifications of the aforementioned are used. The reaction gives 2-methyl-3-acetonitrile-imidazo [1, 2-a] -5,6,7, 8-tetrahydropyridin-8-one as well as 3-methyl-2-acetonitrile-imidazo [1,2 -a] - 5, 6, 7, 8-tetrahydropyridin-8-one, where 2-methyl-3-acetonitrile-imidazo [1,2-a] -5, 6, 7, 8-tetrahydropyridin-8-one is the preferred product is.

4. R3 = methyl in position 6 of the ImidazopyrimidonsySterns ^"or ß-position of the γ-butyrolactone, are used R2 = 4-methylphenyl, R = N, N-dimethylacetamide. Are ß-methyl-γ-butyrolactone and 5-N , N-dimetylacetamide-4- (4-methylphenyl) imidazole or 4-N, N-dimetylacetamide-5- (4-methylphenyl) imidazole or derivatives or modifications of the aforementioned, resulting in N, N, 6-trimethyl 2- (4-methylphenyl) imidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one-3-acetamide as well as N, N, 6-trimethyl 3- (4-methylphenyl) imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one-2-acetamide, where N, N, 6-trimethyl-2- (4-methylphenyl ) - imidazo [1, 2-a] -5,6,7,8-tetrahydropyridin-8-one-3-acetamide is the preferred product.

5. R3 = H, R2 = chlorine, Rl = sulfonyl-3- (4, 6-dimethoxypyrimidin-2-yl) urea). Γ-Butyrolactone and (4-chloroimidazol-5-yl-sulfonyl) -3- (4, 6-dimethoxypyrimidine-

2-yl) urea or (5-chloroimidazol-4-yl-sulfonyl) -3- (4, 6-dimethoxypyrimidin-2-yl) urea or derivatives, precursors or modifications of the aforementioned. The sulfonylurea side chain is preferably built up only after the reaction of imidizole and γ-butyrolactone. For this purpose, the corresponding compound with R1 = sulfonyl would be used as the starting material. 1- (2-Chloro-imidazo [1,2-a] -5, 6, 7, 8-tetra-hydropyridin-8-one-3-yl-sulfonyl) -3- (4, 6-dimethoxypyrimidine- 2-yl) urea and 1- (3-chloro-imidazo [1,2-a] -5, 6, 7, 8-tetra-hydropyridin-8-one-2-yl-sulfonyl) -3- (4th , 6-dimethoxypyrimidin-2-yl) urea, where 1- (2-chloro-imidazo [1, 2-a] -5, 6, 7, 8-tetrahydropyridin-8-one-3-yl-sulfonyl) - 3- (4, 6-dimethoxy-pyrimidin-2-yl) urea is the preferred product.

6. R3 = H, R2 = ethylsulfonyl, Rl = sulfonyl-3- (4, 6-dimethoxypyrimidin-2-yl) urea). Γ-Butyrolactone and: (4-ethylsulfonylimidazol-5-yl-sulfonyl) -3- (4, 6-dimethoxy-pyrimidin-2-yl) -urea or (5-ethylsulfonylimidazol-4-yl-sulfonyl) -3 are used - (4, 6-dimethoxypyrimidin-2-yl) urea or derivatives, precursors or modifications of the aforementioned. The sulfonylurea side chain is preferably built up only after the reaction of imidazole and γ-butyrolactone. For this purpose, the corresponding compound with R1 = sulfonyl would be used as the starting material. 1- (2-Ethylsulfonyl-imidazo- [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one-3-yl-sulfonyl) -3- (4, 6-dimethoxypyrimidin-2) is formed -yl) urea and l- (3-ethylsulfonylimidazo [1, 2-a] -5,6,7, 8-tetrahydropyridin-8-one-2-ylsulfonyl) -3- (4, 6-dimethoxypyrimidin-2-yl) urea, where 1- (2-ethylsulfonylimidazo [1, 2-a] -5,6,7, 8-tetrahydropyridin-8-one-3-yl-sulfonyl) -3 - (4, 6-dimethoxypyrimidin-2-yl) urea is the preferred product.

, R3 = H, R2 = methyl, Rl = amino. 4-methyl-5-aminoimidazole or 5-methyl-4-aminoimidazole and γ-butyrolactone or derivatives or modifications of the aforementioned are used. For example, the amino function can be protected in the form of an amide. 3-Amino-2-methyl-imidazo

[1, 2-a] -5, 6, 7, 8-tetrahydropyridin-8-one and 2-amino-3-methylimidazo [1, 2-a] -5, 6, 7, 8-tetrahydropyridin-8 -on, where 3-Amino-2-methyl-imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one is the preferred product.

8. R3 = H, Rl = formyl, R2 = methyl. Be used

5 4-methyl-5-formylimidazole or 5-methyl-4-formylimidazole and γ-butyrolactone or derivatives or modifications of the aforementioned. For example, the carbonyl function can be protected in the form of an acetal. The result is 3-formyl-2-methyl-imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-10 8-one and 2-formyl-3-methyl-imidazo [1, 2-a] -5, 6, 7, 8-tetrahydropyridin-8-one, with 3-formyl-2-methylimidazo [1, 2-a] - 5, 6, 7, 8-tetrahydropyridin-8-one being the preferred Product is.

9. R3 = H, Rl = hydroxymethyl, R2 = methyl. 15 4-methyl-5-hydroxymethylimidazole or 5-methyl-4-hydroxymethylimidazole and γ-butyrolactone or derivatives or modifications of the aforementioned are used. For example, the hydroxy function can be protected in the form of an ester. The result is 3-hydroxymethyl-2-methyl-imidazo [1,2-a] - 20 5, 6, 7, 8-tetrahydropyridin-8-one and 2-hydroxymethyl-3-methyl-imidazo [1, 2-a] -5,6,7,8-tetrahydropyridin-8-one, with 3-hydroxymethyl-2-methylimidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one being the preferred Product is.

25 10. R3 = methyl in position 7 of the imidazopyrimidone system, R2 = methyl, Rl = amino. 4-Amino-5-methyl-imidazole or 5-amino-4-methyl-imidazole and α-methyl-γ-butyro-lactone or derivatives or modifications of the aforementioned are used. For example, the amino function can be in the form of an amide

30 are protected. 3-Amino-2, 7-dimethyl-imidazo [1, 2-a] -5, 6,7, 8-tetrahydropyridin-8-one and 2-amino-3,7-dimethyl-imidazo [1,2 -a] -5,6,7,8-tetrahydropyridin-8-one, where 3-amino-2,7-dimethylimidazo [1,2-a] -5,6,7,8-tetrahydropyridine- 8-one is the preferred product. 5

11. R3 = H, Rl = formyl (carbonyl), R2 = H. 5-formylimidazole or 4-formylimidazole and γ-butyrolactone and derivatives or modifications of the aforementioned are used. For example, the carbonyl function can be protected in the form of an acetal 0. For example, imidazoT-4-acetate (available, for example, from SIGMA-ALDRICH) or esters of this compound can also be used, which are reductively converted to formyl after the reaction - if appropriate after saponification. 3-Formylimidazo [1, 2-a] -5, 6, 7, 8- 5 tetrahydropyridin-8-one and 2-formylimidazo [1, -a] -5, 6, 7, 8- tetrahydropyridin-8-one, with 3-formylimidazo [1,2-a] -5, 6, 7, 8-tetrahydropyridin-8-one being the preferred product.

12. R3 = methyl in position 7 of the imidazopyrimidone system, Rl =

5 formyl (carbonyl), R2 = H. 5-formylimidazole or 4-formylimidazole and α-methyl-γ-butyrolactone or derivatives or modifications of the aforementioned are used. For example, the carbonyl function can be protected in the form of an acetal. For example, imidazole-4-acetate

10 (available from SIGMA-ALDRICH) or esters of this compound, which are reductively converted to formyl after the reaction - if appropriate after saponification. 3-Formyl-7-methyl-imidazo [1, 2-a] -5,6,7, 8-tetra-hydropyridin-8-one and 2-formyl-7-methyl-imidazo [1,2-a ] -

15 5,6,7,8-tetrahydropyridin-8-one, with 3-formyl-7-methylimidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one being the preferred product ,

13. R3 = H, Rl = R2 = ethoxycarbonyl. 4,5-Di- 20-ethoxycarbonylimidazole and γ-butyrolactone or derivatives or

Modifications to the above. 2, 3-Diethoxycarbonyl imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one is formed.

14. R3 = H, Rl = R2 = (N, N-diethylamino) carbonyl. 4,5- (N, N-diethylamino) carbonylimidazole and γ-butyro-lactone or derivatives or modifications of the aforementioned are used. 2, 3- (N, N-diethylamino) carbonyl-imidazo [1,2-a] - 5,6,7, 8-tetrahydropyridin-8-one is formed.

30 15. R3 = Dimethylaird.no in position 7 of the imidazopyrimidone system, Rl = methyl, R2 = H. 4-methylimidazole or 5-methylimidazole and α-dimethylamino- ^ y-butyrolactone or derivatives or modifications of the aforementioned are used. 7-Dimethylamino-2-methyl-imidazo [1,2-a] -5,6,7, 8-tetrahydro-

35 pyridin-8-one and 7-dimethylamino-3-methyl-imidazo [1, 2-a] - 5,6,7,8-tetrahydropyridin-8-one, whereby 7-dimethylamino-2-methyl-imidazo [1 , 2-a] -5,6,7, 8-tetrahydropyridin-8-one is the preferred product.

40 16. R3 = methyl in position 7 of the imidazopyrimidone system ^" , ^™ Rl = R2 = ethoxycarbonyl. 4,5-diethoxyimidazole and α-methyl-γ-butyrolactone or derivatives or modifications of the aforementioned are used. 2,3-diethoxycarbonyl is formed -7-methylimidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one.

45 17. R3 = methyl in position 7 of the imidazopyrimidone system, Rl = methyl, R2 = H. 4-methylimidazole or 5-methylimidazole and α-methyl-γ-butyrolactone or derivatives or modifications of the aforementioned are used. 2,7-Diethyl-imidazo [1, 2-a] -5, 6,7, 8-tetrahydropyridin-8-one and

3, 7-dimethyl-imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one, with 2, 7-dimethyl-imidazo [1,2-a] -5,6,7 , 8-tetrahydropyridin-8-one is the preferred product.

Derivatives and modifications in relation to the above-mentioned starting materials for the production of the preferred imidazo [1,2-a] -5, 6,7, 8-tetrahydropyridin-8-one means, for example, such chemical changes that increase the stability of the starting materials under the reaction conditions grant the inventive method. For example, a carbonyl or formyl group can be protected in the form of an acetal.

4, 5-substituted imidazoles are accessible in various ways known to those skilled in the art. Syntheses are described in Houben-Weyl, Methods of Organic Chemistry, Volume E8c, Hetarene III - Part 3, 4th Edition, ed. E. Schaumann, Georg Thieme Verlag Stuttgart, 1994, Chapter 1, pp. 1-192. Other methods are described in M. Ross Grimmett (1997) Imidazole and Benzimidazole Synthesis, Academic Press, Inc., San Diego, CA, USA. Various imidazoles can be purchased commercially (e.g. 4-methylimidazole, 4-phenylimidazole, imidazole-4, 5-dicarboxylic acid, imidazole-4-acetate from SIGMA-ALDRICH / Fluka, histamine, histidine from Aldrich).

Substituted γ-butyrolactones are accessible in the manner familiar to the person skilled in the art, inter alia from substituted 1,4-butanediols or substituted tetrahydrofurans. Common synthetic processes are described, among others, in Houben-Weyl "Methods of Organic Chemistry" Volume 6/2 Oxygen Compounds I Part 2; Author H. Kröper; Pp. 571ff, 1963. Substituted γ-butyrolactones can be obtained, for example, from tetrahydrofurans or substituted γ-halogenated butyric acid derivatives, such as 4-bromobutyric acid. Various syntheses are known to the person skilled in the art (JACS 51; 260 (1929); JACS 52; 3702-4 (1930); JACS 63; 2488 (1941); JACS 71; 2825-26 (1949); JACS 80; 6682-84; CA 53; ^" 15050; CA 54; 4393i; CA 59; 11234e).

For example, the following γ-butyrolactones or γ-butyrolactones derived or derivatized from these by synthetic steps known to the person skilled in the art can be used, which (for the games can be purchased commercially from SIGMA-ALDRICH or FLUKA):

γ-butyrolactone α-methyl-γ-butyrolactone γ-methyl1-γ-butyro1actone (γ-valero1actone) α-methylene-γ-butyrolactone (tulipane) γ-methylene-γ-butyrolactone (a '-angelicalactone) γ-ethyl-γ -b tyrolactone (γ-caprolactone) γ-propyl-γ-butyrolactone γ-penty1-γ-butyro1actone γ-hexyl-γ-b tyrolactone γ-hepty1-γ-butyrolactone γ-octyl-γ-b tyrolactone γ-phenyl-γ butyrolactone

R (-) -γ-ethoxycarbonyl-γ-butyrolactone γ-jasmolactone (cis-γ- (3-hexen-l-yl) butyrolactone) γ- (2-naphthyl) -γ-b tyrolactone α, α-diphenyl-γ -butyro1actone α-acryloyloxy-ß, ß-dimethyl-γ-butyrolactone α-hydroxy-ß, ß-dimethyl-γ-butyrolactone

4-hydroxy-2, 2-diphenyl-γ-butyrolactone α-amino-γ-butyro1actone

(S) -2-amino-4-butyrolactone (L-homoserine lactone) 2- (Z-amino) -4-butyrolactone α-hydroxy-γ-butyro1actone ß-hydroxy-γ-butyrolactone γ-hydroxymethyl-γ-butyrolactone γ- Trityloxymethyl-γ-butyrolactone γ-tosyloxymethyl-γ-butyrolactone γ-ethoxycarbonyl-γ-butyrolactone γ-carboxy-γ-butyrolactone

2-Acetylbutyrolactone

2-bromo-γ-butyrolactone α-bromo-α-methyl-γ-butyrolactone

2-Bromo-4-hydroxy-γ-butyrolactone

Pantolactone (2-hydroxy-3, 3-dimethyl-γ-butyrolactone) α-acetyl-α-methyl-γ-butyrolactone γ-phenyl-α-trifluoromethyl-γ-butyrolactone α-benzylidene-γ-butyrolactone ^~ ~

If the γ-butyrolactone to be used contains a chiral center, one of the two enantiomers is preferably used. Another object of the invention relates to the use of the imidazo [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-ones of the formula Ia or Ib according to the invention for the preparation of imidazo [1, 2a] pyridines, preferably according to the general formula IV, and of compounds of the general formula V and their preliminary or intermediate stages.

IV V

The following applies to the general formula IV:

a) for the radicals Rl, R2 or each R3 in each case and independently of one another the definitions given above, and

b) A is 0 or NH, and

c) R4 is substituted or unsubstituted, branched or unbranched -C-Cg-alkyl, C ₂ -Cg-alkenyl, C-Cg-alkynyl, C ₃ -C ₇ -cycloalkyl, C ₃ -Cg-alkadienyl, halo-Cι-C ₆ -alkyl,

Ci-Cg-alkoxy, C ₂ -Cg-alkenyloxy, C ₂ -Cg-alkynyloxy, Ci-Cg-alkyl-oxy-Ci-Cg-alkyl, Cι-Cg-alkyl-oxy-C ₂ -Cg-alkenyl, Ci -C _ß -alkyl-oxy-C ₂ -Cg-alkynyl, cyano-Ci-Cg-alkyl, isocyano-Ci-Cg-alkyl, amino-Ci-Cg-alkyl, amino-C-Cg-alkynyl, CO-Ci -Cg-alkyl, carboxyl, Ci-Cg-alkylcarboxyl, substituted or unsubstituted aryl, arylalkyl, heteroaryl and heteroarylalkyl.

The following applies to the general formula V:

b) R5a and R5b is selected from the group consisting of hydrogen, hydroxyl, -CC ₆ alkoxy, Ci-Cg-alkoxy-Ci-Cg-alkoxy, Ci-Cg-alkylcarbonyloxy. R5a and R5b together can also be oxygen (oxo group), and

c) R6a and R6b is selected from the group consisting of hydrogen, hydroxyl, Ci-Cg-alkoxy, Ci-Cg-alkoxy-Ci-Cg-alkoxy, Ci-Cg-alkylcarbonyloxy, wherein at least one of the radicals R6a or R6b is hydrogen is. R6a and R6b together can also be oxygen (oxo group), and d) R7 is hydrogen, halogen, Ci-Cg-alkyl, Cχ-Cg-alkoxy,

Cι-Cg_alkoxycarbonylamino, -CC ₆ -alkoxy-Cχ-C ₆ -alkoxycarbonylamino or trifluoromethyl, and

e) R8 is hydrogen, halogen, Ci-Cg-alkyl, Cι-Cg_alkoxy or salts thereof.

Particularly preferred compounds of the general formula IV are mentioned in Kaminski JJ et al. (1987) J Med Chem 30: 2031-2046; DE 28 20 938, WO 98/54188, WO 98/37080, DE 19602853, EP 0 308 917, EP 0 268 989, US 6,124,313, US 6,096,758, WO 96/03405, WO 96/03402, US 5,574,042, WO 95 / 10518, EP 596 406, WO 94/18199, WO 89/00570, EP 0 290 003, EP 0 228 006, EP 0 204 285, EP 068 378, EP 033 094, US 6,132,768.

Particularly preferred compounds of the general formula V are mentioned in WO 98/42707.

These compounds are accessible using methods familiar to the person skilled in the art, in accordance with the reactions shown in schemes A to C.

For example, starting from an imidazo [1,2-a] -

5, 6, 7, 8-tetrahydropyridin-8-one can be formed by reaction with alkyl or arylamines to form the base of the ship. The amine is preferably used in excess and the reaction is carried out under acidic catalysis, for example with p-toluenesulfonic acid (as described, for example, in: Organikum, Deutscher Verlag der Wissenschaften (1990), Chapter 7.1.1). The Schiff's bases (enamines) obtained can then be converted to substituted 8-amino-imidazo [1,2a] pyridines according to Reaction Scheme A (II) by oxidative aromatization. Alternatively, imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one can be converted to ^' imidazo [1,2a] pyridines by reaction with ammonia and subsequent oxidative aromatization, and the preferred compounds by reaction, for example obtained with haloalkylene or arylene (Scheme A (I)). 8-Hydroxy-imidazo [1, 2a] pyridines are directly accessible through oxidative aromatization.

Oxidative aromatization can be achieved, for example, by reaction with 2,3-dichloro-5, 6-dicyanobenzoquinone (DDQ) in the manner familiar to the person skilled in the art (review article: Walker D. et al. (1967) Chem. Rev. 67: 153-195 ). Bromination and subsequent HBr cleavage can be used as a further flavoring variant. The reactions of 8-hydroxy-imidazo [1,2a] pyridines or 8-amino-imidazo [1,2a] pyridines according to reaction scheme A (I) or B are carried out using hydroxy- or haloalkylene or -arylene - optionally after in situ Derivatization or activation - is described for example in US 6,124,313, EP 0 033 094, EP 0 308 917 or EP 0 268 989.

For example, 2,3-dimethyl-imidazo [1,2-a] -5, 6, 7, 8-tetra-hydropyridin-8-one can be reacted with alkyl or aryl halides, preferably alkyl or aryl bromides, and then aromatized by oxidation to 2, 3-dimethyl-8-alkyl / aryloxy-imidazo- [1, 2-a] pyridines. Furthermore, a reaction of 2, 3-dimethyl-imidazo [1, 2-a] -5,6,7, 8-tetrahydropyridin-8-oen with alkyl or arylamines and subsequent aromatization by oxidation to 2,3-dimethyl 8-alkyl / arylamino-imidazo [1, 2-a] pyridines take place.

2-methyl-3-acetonitrile-imidazo [1,2-a] pyridin-8-one can be converted into 2-methyl-8- (phenylmethoxy) imidazo [1,2-a] by reaction with bromomethylbenzene and subsequent aromatization by oxidation. - Pyridine-3-acetonitrile are implemented. A promising compound for the treatment of gastric ulcers. The compound is known under the name SCH-28080 and acts as an inhibitor of gastric H +, K + -ATPase. N, N, 6-trimethyl-2- (4-methylphenyl) imidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one-3-acetamide can be reduced by reducing the oxo Group and subsequent elimination and aromatization to N, N, 6-trimethyl-2- (4-methylphenyl) imidazo [1,2-a] pyridine-3-acetamide. The compound is commercially available under the name Zolpidem (Arabia ^® ) as a non-benzodiazepine benzodiazepine agonist.

1- (2-chloro-imidazo [1,2-a] -5, 6, 7, 8-tetrahydropyridin-8-one-3-yl-sulfonyl) -3- (4, 6-dimethoxypyrimidin-2-yl) -Urea can be reduced to the imazosulfuron ^® (1- (2-chloro-imidazo [1,2-a] - pyridin-3-yl-sulfonyl) -3- (4,6- dimethoxypyrimidin-2-yl) urea) are implemented.

1- (2-ethylsulfonylimidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one-3-yl-sulfonyl) -3- (4, 6-dimethoxypyrimidin-2-yl) -Urea can be reduced by reduction of the oxo group and subsequent elimination and aromatization to Sulfosulfuron ^® (1- (2-ethylsulfonyl-imidazo [1,2-a] pyridin-3-yl-sulfonyl) -3- (4, 6-demethoxypyrimidine - 2-yl) urea) are implemented.

3-Amino-2-methyl-imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one can be converted to 3-amino-2-methyl- by reaction with, for example, phenylmethylbromide and subsequent aromatization by oxidation. 8— (phenylmethoxy) imidazo [1,2-a] pyridine can be reacted. A reaction with 2-phenylethylmagnesium bromide leads to 3-amino-2-methyl-8- (2-phenylethyl) imidazo [1,2-a] pyridine after subsequent elimination of the hydroxy group and aromatization.

3-formylimidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one can be converted to 3-formyl-8-methylimidazo [1,2. Using methylmagnesium bromide followed by aromatization with elimination of the hydroxy group -a] pyridine are implemented. This compound is suitable as an intermediate for the production of C-nucleoside analogs (as described in Pan SF et al. (1998) Tetrahedron Letters 39: 8191-8194).

3-Formyl-7-methyl-imidazo [1,2-a] -5,6,7, 8-tetrahyropyridin-8-one can be reduced to 3-formyl-7-methyl after reduction of the keto group and subsequent aromatization with elimination of the hydroxy group -imidazo- [1, 2-a] pyridine are implemented. This compound is suitable as an intermediate for the production of C-nucleoside analogs (as described in Pan SF et al. (1998) Tetrahedron Letters 39: 8191-8194). Also particularly preferred is the preparation of the compounds mentioned in EP 0 930 062, preferably the ones described below, for use in hair cosmetics, starting from the imidazo [1,2-a] -5,6,7, 8-tetrahyropyridin-8-ones according to the invention :

1. 8-hydroxy-2, 3-dimethyl-imidazo [1, 2-a] pyridine. Made from

2, 3-Dimethyl-imidazo [1,2-a] -5,6,7, 8-tetrahyropyridin-8-one by means of oxidative aromatization.

2. 8-amino-2,3-dimethyl-imidazo [1,2-a] pyridine. Preparation from 2, 3-dimethyl-imidazo [1,2-a] -5,6,7, 8-tetrahyropyridin-8-one by reaction with ammonia and oxidative aromatization.

3. 8-hydroxy-3-hydroxymethyl-2-methylimidazo [1,2-a] pyridine. Preparation from 3-hydroxymethyl-2-methyl-imidazo [1,2-a] -

5, 6,7, 8-tetrahydropyridin-8-one by means of oxidative aromatization.

4. 2-methyl-3-hydroxymethyl-8-amino-imidazo [1,2-a] yridine. Preparation from 3-hydroxymethy1-2-methy1-imidazo [1,2-a] -

5, 6, 7, 8-tetrahydropyridin-8-one by means of reaction with ammonia and oxidative aromatization.

5. 8-Hydroxy-2,3-diethoxycarbonyl-imidazo [1,2-a] pyridine. Preparation from 2,3-diethoxycarbonyl-imidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one by means of oxidative aromatization.

6. 8-amino-2,3-diethoxycarbonyl-imidazo [1,2-a] pyridine. Preparation from 2,3-diethoxycarbonyl-imidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one by reaction with ammonia and oxidative aromatization.

7. 8-Hydroxy-7-dimethylamino-2-methylimidazo [1,2-a] pyridine. Preparation from 7-dimethylamino-2-methyl-imidazo [1,2-a] - 5,6,7, 8-tetrahydropyridin-8-one by means of oxidative aromatization.

8. ^• 8-amino-7-dimethylamino-2-methylimidazo [1, 2-a] pyridine. Preparation from 7-dimethylamino-2-methyl-imidazo [1,2-a] - 5, 6,7, 8-tetrahydropyridin-8-one by reaction with ammonia and oxidative aromatization.

9. 8-Hydroxy-2,3-diethoxycarbonyl-7-methylimidazo [1,2-a] pyridine. Preparation from 2,3-diethoxycarbonyl-7-methylimidazo [1,2-a] -5,6,7,8-tetrahydropyridin-8-one by means of oxidative aromatization. 10. 8-amino-2,3-diethoxycarbonyl-7-methylimidazo [1,2-a] yridine.

Preparation from 2,3-diethoxycarbonyl-7 ~ methyl-imidazo-

[1,2-a] -5, 6, 7, 8-tetrahydropyridin-8-one by reaction with ammonia and oxidative aromatization. 5

11. 2, 7-Dimethyl-8-hydroxy-imidazo [1,2-a] pyridine. Made from

2,7-dimethyl-imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one by means of oxidative aromatization.

10 12. 2, 7-Dimethyl-8-amino-imidazo [1,2-a] pyridine. Preparation from 2,7-dimethyl-imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one by reaction with ammonia and oxidative aromatization.

13. 8-Hydroxy-2,3-bis (N, N-diethylamino) carbonyl-imidazo [1,2-a] - 15 pyridine. Preparation from 2,3- (N, N-diethylamino) carbonylimidazo [1, 2-a] -5,6,7, 8-tetrahydropyridin-8-one by means of oxidative aromatization.

14. 8-amino-2,3-bis (N, N-diethylamino) carbonylimidazo [1,2-a] - 0 pyridine. Preparation from 2,3- (N, N-diethylamino) carbonylimidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one by reaction with ammonia and oxidative aromatization.

15. (8-Hydroxy-2-methylimidazo [1, 2-a] pyridin-3-yl) acetonitrile. 5 Preparation from 2-methyl-3-acetonitrile-imidazo [1,2-a] -

5, 6,7, 8-tetrahydropyridin-8-one by means of oxidative aromatization.

16. (8-Amino-2-methylimidazo [1,2-a] pyridin-3-yl) acetonitrile. 0 Preparation from 2-methyl-3-acetonitrile-imidazo [1,2-a] -

5, 6,7, 8-tetrahydropyridin-8-one by means of reaction with ammonia and oxidative aromatization.

Preferred compounds of the general formula V are mentioned in 5 WO 98/42707. In particular, the compounds according to the invention 3-formyl-2-methylimidazo [1,2-a] -5, 6, 7, 8-tetrahydropyridin-8-one, 3-hydroxymethyl-2-methylimidazo [1, 2-a] -5,6,7,8-tetrahydropyridin-8-one or 2,3-dimethyl-imidazo [1, 2-a] -5,6,7,8-tetrahydropyridin-8-one according to reaction scheme C. be converted to one of the following 0 connections: ^~ ~

2, 3-dimethyl-imidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one to:

a) 2,3-Dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo [1,2-h] [1,7] - 5 naphthyridin-7-one. b) 9- (2-Chlorophenyl) -2, 3-dimethyl-7, 8,9, 10-tetrahydroimidazo- [1,2-h] [1,7] naphthyridin-7-one.

c) 9- (2, 6-dichlorophenyl) -2, 3-dimethyl-7, 8,9, 10-tetrahydroimidazo [1, 2-h] [1, 7] naphthyridin-7-one.

d) 9- (2-Trifluoromethylphenyl) -2, 3-dimethyl-7, 8,9, 10-tetra-hydroimidazo [1, 2-h] [1,7] naphthyridin-7-one.

e) 7-Hydroxy-2, 3-dimethyl-9-phenyl-, 8.9, 10-tetrahydroimidazo- [1,2-h] [1,7] naphthyridine.

f) 9- (2-Chlorophenyl) -7-hydroxy-2, 3-dimethyl-7, 8.9, 10-tetra-hydroimidazo [1,2-h] [1,7] naphthyridine.

g) 9- (2, 6-dichlorophenyl) -7-hydroxy-2, 3-dimethyl-7, 8,9, 10-tetrahydroimidazo [1, 2-h] [1,7] naphthyridine.

h) 9- (2-Trifluoromethylphenyl) -7-hydroxy-2, 3-dimethyl-7, 8,9, 10-tetrahydroimidazo [1, 2-h] [1, 7] naphthyridine.

i) 8-Hydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo- [1,2-h] [1,7] naphthyridin-7-one.

j) 7,8-Dihydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo [1,2-h] [1,7] naphthyridine.

k) 7, 8-isopropylidenedioxy-2,3-dimethyl-9-phenyl-7, 8,9, 10-tetra-hydroimidazo [1, 2-h] [1,7] naphthyridine.

3-Formyl-2-methyl-imidazo [1,2-a] -5, 6, 7, 8-tetrahydropyridin-8-one to:

a) 3-Formyl-8-hydroxy-2-methyl-7-oxo-9-phenyl-7, 8,9, 10-tet a-hydroimidazo [1,2-h] [1, 7] naphthyridine.

The formyl group is preferably used as acetal in a protected manner.

3-hydroxymethyl-2-methylimidazo [1,2-a] -5,6,7, 8-tetrahydropyridin-8-one to:

a) 3-hydroxymethyl-7, 8-dihydroxy-2-methyl-9-phenyl-7, 8,9, 10-tetrahydroimidazo [1,2-h] [1, 7] naphthyridine. The hydroxymethyl group is preferably used protected in the form of an ether or ester.

Example 1: Preparation of 2, 3-dimethyl-imidazo [1, 2a] - 5, 6, 7, 8-tetrahydro-pyridin-8-one

25 mol (2130 g) of distilled γ-butyrolactone were distilled in a 4-1 four-necked flask. (corresponding to 1.89 l) and 5 moles (500 g) 4, 5-dimethylimidazole (96%) were introduced. The mixture was heated to 190 ° C. to 200 ° C. and stirred for 10 hours under a protective gas atmosphere (nitrogen flow of about 15 l / h), the temperature being raised continuously to 215 ° C. The water of reaction formed and excess butyrolactone were distilled off (amount of distillate: approx. 1000 g).

After 10 hours, a sample of the reaction mixture was examined by gas chromatography for the desired product. If the result was positive, the reaction mixture was cooled to 25 ° C. within 8 hours. The reaction mixture was filtered through an 18 cm porcelain suction filter. The filter cake was washed with 100 g of γ-butyrolactone over the reaction flask and sucked dry. The filter cake was then stirred in 450 g of acetone, suction filtered again and washed with 50 g of acetone. After vacuum drying, the filter cake is dried at 70 ° C in a vacuum. This yield was 30% based on the imidazole.

Example 2: Preparation of 2-methylimidazo [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-one and 3-methylimidazo [1,2a] -

5,6,7,8-tetrahydropyridin-8-one

0.75 mol (64.5 g) of distilled γ-butyrolactone was placed in a 250 ml three-necked flask and 0.15 mol (12.3 g) of 4-methylimidazole (97%) was introduced. The reaction vessel was rendered inert with nitrogen and a continuous nitrogen flow of about 10 l / h was passed over during the reaction. The reaction mixture was heated to 190 ° C. in the course of 2 hours with stirring and kept at this temperature for a further 8 hours. During the reaction time, about 5 g of distillate consisting of water which is formed during the reaction and γ-butyrolactone were collected. The reaction mixture was cooled and the discharge on the rotary evaporator was concentrated until no more γ-butyrolactone passed over. The two isomeric reaction products were isolated by bulb tube distillation of the bottom at 180 ° C. and 0.4 mbar. 4.5 g (0.03 mol; 20% of the theoretical maximum yield) of 2-methylimidazo [1, 2a] -5, 6, 7, 8-tetrahydropyridin-8-one and 3-methylimidazo [1,2a ] -5, 6,7, 8-tetrahydropyridin-8-one in the ratio of approx. 1: 1 (according to NMR) as a light oil ⁵ .

Example 3: Preparation of 2, 3-diphenyl-5, 6, 7, 8-tetrahydroimidazo [1, 2a] pyridin-8-one

0.3 mol (26 g) of distilled butyrolactone (corresponding to 23 ml) was placed in a 100 ml four-necked flask and 0.1 mol (22 g) of 4,5-diphenylimidazole was introduced. Under a protective gas atmosphere, the mixture was heated to 180 ° C. and stirred for 20 hours. The water of reaction formed was distilled off in the course of this.

After 20 hours, a sample of the reaction mixture was examined by gas chromatography for the desired product. If the result was positive, the reaction mixture was cooled to 80 ° C. within 5 hours. The mixture was filtered through a fine 5.5 cm glass filter at 80 ° C. The filter cake was washed with 10 g of butyrolactone over the reaction flask and sucked dry. The filter cake was then washed with 15 g of acetone. After suction drying, the filter cake was dried at 70 ° C. in vacuo. The yield in this experiment was 19% based on the imidazole. 2, 3-Diphenyl-5, 6,7, 8-tetrahydroimidazo [1, 2a] pyridin-8-one was obtained and NMR identified.

Claims

claims

1 . Process for the preparation of imidazo- [1, 2a] -5, 6, 7, 8-tetrahydro-pyridin-8-ones, characterized in that

b) the imidazo- [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-one isolated.

2. The method according to claim 1, characterized in that the reaction mixture is heated to temperatures above 100 ° C.

3. The method according to any one of claims 1 or 2, characterized in that the reaction mixture is heated to temperatures of 150 ° C to 250 ° C.

4. The method according to any one of claims 1 to 3, characterized in that the γ-butyrolactone is used in excess.

5. The method according to any one of claims 1 to 4, characterized in that the γ-butyrolactone is used as solvent and during or after the reaction, the water of reaction and part or all of the excess γ-butyrolactone is removed.

6. The method according to any one of claims 1 to 5, characterized in that the imidazo- [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-one has the general formula Ia or Ib, the imidazole has the general formula Ha or Ilb and the γ-butyrolactone has the general formula III,

Ia Ib

Ha Hb III

and Rl, R2 or each R3 is selected independently and independently of one another from the group consisting of hydrogen, halogen, hydroxy, cyano, isocyano, thiocyano, amino, nitroso, nitro, carbonyl, alkylcarbonyl, sulfonate, alkylsulfonyl, sulfonamide, sulfonylurea, carboxyl , Alkylcarboxyl, substituted or unsubstituted, branched or unbranched or cyclic alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl or heteroaryl, where the number of substituents R3 can have a value n of 1 to 6.

7. The method according to claim 6, characterized in that Rl, R2 or each R3 is selected independently and independently of one another from the group consisting of hydrogen, hydroxy, halogen, cyano, thiocyanato, branched or non-branched, optionally substituted C 1 -C 6 Alkyl, C ₂ -Cg alkenyl,

CC-alkynyl, C ₃ -C -cycloalkyl, C ₃ -Cg-alkadienyl, hydroxy-Cχ-C ₆ -alkyl, halo-Cχ-Cg-alkyl, Ci-Cg-alkoxy, C ₂ -Cg-alkenyloxy,. C -C ₆ -alkynyloxy, Ci-Cg-alkyl-oxy-Ci-Cg-alkyl, Ci-Cg-alkyl-oxy- C ₂ -C ₆ -alkenyl, -C-Cg-alkyl-oxy-C ₂ -Cg- alkynyl, cyano-Ci-Cg-alkyl, isocyano-Ci-Cg-alkyl, amino-Ci-Cg-alkyl, amino-C ₂ -Cg-alkynyl, CO-Cι-Cg_alkyl, Ci-Cg-alkylsulfonyl, mono- or disubstituted N- (Ci-Cg-alkyl) sulfonamide, sulfonylurea, sulfonate, carboxyl, Cι-Cg_alkylcarboxyl, carbonyl, alkylcarbonyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, preferred substituents being halogen, hydroxy, cyano, iso ^¬ cyano, thiocyano , Amino, nitroso, nitro, alkoxy, alkenyloxy, Alkynyloxy, carbonyl or alkylcarbonyl, carboxyl or alkylcarboxyl.

8. The method according to any one of claims 1 to 8, characterized in that Rl and R2 are not hydrogen.

9 .. The method according to any one of claims 1 to 9, characterized in that Rl and R2 are identical and not hydrogen.

10. Substituted imidazo- [1,2a] -5,6,7, 8-tetrahydropyridin-8-one described by the general formula Ia or Ib or salts thereof with the proviso that

a) Rl, R2 and all radicals R3 do not simultaneously represent hydrogen, or

b) if Rl and all radicals R3 represent hydrogen, then R2 is not methyl, or

c) if R2 and all R3 represent hydrogen, then Rl is not methyl, where

Rl, R2 or each R3 is selected in each case and independently of one another from the group consisting of hydrogen,

Hydroxy, halogen, cyano, thiocyanato, branched or unbranched, optionally substituted Ci-Cg-alkyl, C ₂ -Cg-alkenyl, C ₂ -Cg-alkynyl, C ₃ -C -cycloalkyl, C ₃ -Cg-alkadienyl, hydroxy- Ci-Cg-alkyl, halo-Ci-Cg-alkyl, Ci-Cg-alkoxy, C ₂ -Cg-alkenyloxy, C ₂ -Cg-alkynyloxy, Ci-Cg-alkyl-oxy-Ci-Cg-alkyl,

Cι-Cg-alkyl-C ₂ -Cg-alkenyl, Cι-Cg-alkyl-oxy-C ₂ -Cg-alkynyl, cyano-Ci-Cg-alkyl, isocyano-Ci-Cg-alkyl, amino-Ci- Cg-alkyl, amino-C ₂ -Cg-alkynyl, CO-Cχ-C-alkyl, Ci-Cg-alkylsulfonyl, mono- or disubstituted N- (Ci-Cg-alkyl) sulfonamide, sulfonylurea, sulfonate, carboxyl, Cι- C ₆ -alkylcarboxyl, carbonyl, formyl, alkylcarbonyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, preferred substituents being halogen, hydroxy, cyano, isocyanano, thiocyano, amino, nitroso, nitro, alkoxy, alkenyloxy, alkynyloxy, carbonyl or alkylcarbonyl, Carboxyl or alkylcarboxyl, where the number of substituents R3 can have a value n of 1 to 6.

11. Substituted imidazo- [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-one according to claims 10, characterized in that Rl, R2 or each R3 can be independent of one another

i a) Ci-Cg-alkyl selected from the group consisting of methyl, ethyl, n-propyl and iso-propyl.

b) C ₂ -Cg alkenyl selected from the group consisting of ethenyl, 1-propenyl and 2-propenyl.

c) C ₃ -Cg alkadienyl selected from the group consisting of propadienyl and n-butadien-1, 3-yl.

d) C ₂ -Cg alkynyl selected from the group consisting of ethynyl, 1-propynyl and 2-propynyl.

e) Halo-Ci-Cg-alkyl selected from the group consisting of fluoromethyl, fluoroethyl, n-fluoropropyl and iso-fluoropropyl, one or more fluorine substitutions being permitted. Most preferred is trifluoromethyl.

f) hydroxyalkyl selected from the group consisting of hydroxymethyl, hydroxyethyl, n-hydroxypropyl and iso-hydroxypropyl. fg) ^'' -C-Cg_alkoxy selected from the group consisting of methoxy, ethoxy, n-propoxy and iso-propoxy.

h) Cyano-Ci-Cg-alkyl selected from the group consisting of cyanomethyl, cyanoethyl, n-cyanopropyl and iso-cyano-propyl.

i) Isocyano-Ci-Cg-alkyl selected from the group consisting of isocyanomethyl, isocyanoethyl, n-isocyanopropyl and iso-isocyanopropyl.

j) Amino-Ci-Cg-alkyl selected from the group consisting of aminomethyl, aminoethyl, n-aminopropyl and iso-aminopropyl.

k) amino-C ₂ -Cg-alkynyl selected from the group consisting of aminoethynyl, 1-amino-l-propynyl and l-amino-2-propynyl.

1) Alkylsufonyl selected from the group consisting of methylsulfonyl, ethylsulfonyl, n-propylsulfonyl and iso-propylsulfonyl. m) N-mono- or N-disubstituted (Ci-Cg-alkyl) sulfonamides with the proviso that

the "" alkyl substituent is selected from group 5 consisting of methyl, ethyl, n-propyl and iso-propyl or

both substituents on nitrogen are identical.

10 n) l-sulfonyl-3 (4, 6-dimethoxypyrimidin-2-yl) urea.

o) aryl selected from the group consisting of phenyl, tolyl, xylyl, 1-naphthyl, 2-naphthyl, 1-anthryl and 2-anthryl. 15

12. Substituted imidazo- [1,2a] -5,6,7, 8-tetrahydropyridin-8-one according to one of claims 10 or 11, characterized in that Rl and R2 are not hydrogen.

20 13. Substituted imidazo- [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-one according to one of claims 10 to 12, characterized in that Rl and R2 are identical and not hydrogen.

14. Use of an imidazo [1,2a] -5, 6, 7, 8-tetrahydropyridin-8-one 25 according to one of claims 10 to 13 for the preparation of

Imidazo [1,2a] pyridines.

15. Use according to claim 14, wherein the imidazo [1,2a] pyridine is described by the general formula IV

30

and

0 a) for the substituents Rl, R2 or each R3 the definition according to one of claims 8 to 11 applies, the number of substituents R3 can assume a value n of 1 to 3 and

5 b) A is 0 or NH, and c) R4 is selected from the group consisting of substituted or unsubstituted, branched or unbranched Ci-Cg-alkyl, C ₂ -Cg-alkenyl, C ₂ -C -alkynyl, C ₃ -C ₇ - cycloalkyl, C ₃ -C ₆ -Alkadienyl, halo -CC ~ C ₆ -alkyl, Ci-Cg-alkoxy, C ₂ -C ₆ _alkenyloxy, C ₂ -Cg_alkynyloxy, Ci-Cg-alkyloxy-Ci-Cg-alkyl, Cι-Cg_alkyl- oxy-C ₂ -Cg-alkenyl, -C-C ₆ _alkyl-oxy-C ₂ -Cg-alkynyl, cyano-Ci-Cg-alkyl, isocyano-Ci-Cg-alkyl, amino-Ci-Cg-alkyl, Amino-C ₂ -Cg-alkynyl, carboxyl, Ci-Cg-alkylcarboxyl, substituted or unsubstituted aryl, arylalkyl, heteroaryl and heteroarylalkyl.

16. Use according to claim 14, wherein the imidazo [1,2a] pyridine is described by the general formula V.

and'

a) for the substituents Rl, R2 and R3 the definition according to one of claims 8 to 11 applies, wherein the number of substituents R3 can assume a value n of 1 or 2 and

b) R5a and R5b is selected from the group consisting of hydrogen, hydroxyl, C ₁ -C ₆ -alkoxy, C ₁ -C ₆ -alkoxy-C ₁ -C ₆ -alkoxy, C ₁ -C ₆ -alkylcarbonyloxy, R5a and R5b also being ^'together' Can be oxygen (oxo group), and

c) R6a and R6b is selected from the group consisting of hydrogen, hydroxyl, Cι-Cg_alkoxy, Cι-Cg_alkoxy-Cι-Cg_alkoxy, Ci-Cg-alkylcarbonyloxy, at least one of the radicals R6a or R6b being hydrogen and where R6a ^" and R6b together can also be oxygen (oxo group), and

d) R7 is selected from the group consisting of hydrogen, halogen, Ci-Cg-alkyl, Cι-Cg_alkoxy, Cι-Cg_alkoxy-carbonylamino, Cι-Cg_alkoxy-Cι-Cg-alkoxycarbonylamino or trifluoromethyl, and R8 is selected from the group consisting of hydrogen, halogen, Ci-Cg-alkyl, Cι-Cg_alkoxy.